All webinar times are in Eastern Time except where noted. Convert to your timezone.
This webinar is being presented as a collaboration between the Society for Young Clinical Laboratorians (SYCL) and AACC's Pediatric and Maternal Fetal Division and presents a trending laboratory medicine topic through the viewpoint and expertise of an aspiring lab leader.
The use of circulating cell free DNA (cfDNA) for detecting fetal aneuploidy (abnormal number of chromosomes) has become prevalent in high-risk obstetric populations and is increasingly utilized in the general obstetric population. New approaches are now emerging that incorporate cfDNA analysis into routine prenatal screening protocols.
In this webinar Dr. Tina Lockwood of the University of Washington will describe cfDNA screening technologies with an emphasis on the unique biological and analytic challenges that affect test interpretation.
After participating in this webinar, you will be able to:
- Describe the technology driving new applications of cfDNA prenatal aneuploidy screening
- Recognize the computational challenges associated with detecting fetal aneuploidy from cfDNA
- List common causes of false negative and false positive cfDNA screening results
- Recognize and describe secondary or incidental findings that may arise from cfDNA prenatal aneuploidy screening
Who Should Attend
Laboratory directors, managers, and supervisors; residents/trainees, industry professionals and other healthcare providers whose work involves prenatal testing.
Tina Lockwood, PhD
Assistant Professor, Pathology and Laboratory Medicine
University of Washington School of Medicine